Q32 Bio
Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
-- Presented additional 36-week results and 16-week off-drug findings from Part B of the SIGNAL-AA clinical trial of bempikibart in late-breaking…
Company newsroom
Q32 Bio
NASDAQ:QTTB
1 releases